|
1）Sonobe M, Yamazaki T, Yonekura M, et al. Small unruptured intracranial aneurysm verification study: SUAVe study, Japan. Stroke. 2010; 41: 1969-77
|
|
|
|
2）Morita A, Kirino T, Hashi K, et al. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med. 2012; 366: 2474-82
|
|
|
|
|
|
3）Inagawa T. Risk factors for the formation and rupture of intracranial saccular aneurysms in Shimane, Japan. World Neurosurg. 2010; 73: 155-64
|
|
|
|
|
|
4）Kataoka K, Structural fragility and inflammatory response of ruptured cerebral aneurysms. A comparative study between ruptured and un-ruptured cerebral aneurysms. Stroke. 1999; 30: 1396-401
|
|
|
|
|
|
5）Frosen J, Tulamo R, Paetau A, et al. Saccular intracranial aneurysm: pathology and mecha-nisms. Acta Neuropathol. 2012; 123: 773-86
|
|
|
|
|
|
6）Kondo S, Hashimoto N, Kikuchi H, et al. Apoptosis of medial smooth muscle cells in the development of saccular cerebral aneurysms in rats. Stroke. 1998; 29: 181-8
|
|
|
|
|
|
7）Sadamasa N, Nozaki K, Hashimoto N. Disruption of gene for inducible nitric oxide synthase reduces progression of cerebral aneurysms. Stroke. 2003; 34: 2980-4
|
|
|
|
|
|
8）Moriwaki T, Takagi Y, Sadamasa N, et al. Impaired progression of cerebral aneurysms in interleukin-1beta-deficient mice. Stroke. 2006; 37: 900-5
|
|
|
|
|
|
9）Aoki T, Nishimura M. Targeting chronic inflam-mation in cerebral aneurysms focusing on NF-kappaB as a putative target of medical therapy. Expert Opin Ther Targets. 2010; 14: 265-73
|
|
|
|
|
|
10）Jayaraman T, Paget A, Shin YS, et al. TNF-alpha-mediated inflammation in cerebral aneurysms: a potential link to growth and rupture. Vasc Health Risk Manag. 2008; 4: 805-17
|
|
|
|
|
|
11）Tulamo R, Frosen J, Junnikkala S, et al. Complement system becomes activated by the classical pathway in intracranial aneurysm walls. Lab Invest. 2010; 90: 168-79
|
|
|
|
|
|
12）Laaksamo E, Ramachandran M, Frosen J, et al. Intracellular signaling pathways and size, shape, and rupture history of human intracranial aneu-rysms. Neurosurgery. 2012; 70: 1565-72
|
|
|
|
|
|
13）Maderna E, Corsini E, Franzini A, et al. Expression of vascular endothelial growth factor receptor-1/-2 and nitric oxide in unruptured intracranial aneurysms. Neurol Sci. 2010; 31: 617-23
|
|
|
|
|
|
14）Nakaoka H, Takahashi T, Akiyama K, et al. Differential effects of chromosome 9p21 variation on subphenotypes of intracranial aneurysm: site distribution. Stroke. 2010; 41: 1593-8
|
|
|
|
|
|
15）McColgan P, Thant KZ, Sharma P. The genetics of sporadic ruptured and unruptured intracranial aneurysms: a genetic meta-analysis of 8 genes and 13 polymorphisms in approximately 20,000 individuals. J Neurosurg. 2010; 112: 714-21
|
|
|
|
|
|
16）Roder C, Kasuya H, Harati A, et al. Meta-analysis of microarray gene expression studies on intra-cranial aneurysms. Neuroscience. 2012; 201: 105-13
|
|
|
|
|
|
17）Kurki MI, Häkkinen SK, Frosen J, et al. Upregulated signaling pathways in ruptured human saccular intracranial aneurysm wall: an emerging regulative role of Toll-like receptor signaling and nuclear factor-κB, hypoxia-inducible factor-1A, and ETS transcription factors. Neurosurgery. 2011; 68: 1667-75
|
|
|
|
|
|
18）青木友浩，野崎和彦. 未破裂脳動脈瘤に対する薬物療法. In: 神経疾患最新の治療 2012-2014. 東京: 南江堂; 2012. p.6-9
|
|
|
|
|
|
19）Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneu-rysms. Circulation. 2008; 117: 1883-9
|
|
|
|
|
|
20）Aoki T, Kataoka H, Ishibashi R, et al. Simvastatin suppresses the progression of experimentally induced cerebral aneurysms in rats. Stroke. 2008; 39: 1276-85
|
|
|
|
|
|
21）Aoki T, Kataoka H, Ishibashi R, et al. Pitavastatin suppresses the formation and progression of cerebral aneurysms through the inhibition of nuclear factor kappa B pathway. Neurosurgery. 2009; 64: 357-66
|
|
|
|
|
|
22）Tada Y, Kitazato KT, Yagi K, et al. Statins promote the growth of experimentally induced cerebral aneurysms in estrogen-deficient rats. Stroke. 2011; 42: 2286-93
|
|
|
|
|
|
23）Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008; 70: 2364-70
|
|
|
|
|
|
24）Marbacher S, Schläppi JA, Fung C, et al. Do statins reduce the risk of aneurysm develop-ment? A case-control study. J Neurosurg. 2012; 116: 638-42
|
|
|
|
|
|
25）Risselada R, Straatman H, van Kooten F, et al. Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke. 2009; 40: 2887-92
|
|
|
|
|
|
26）Aoki T, Nishimura M, Kataoka H, et al. Role of angiotensin II type 1 receptor in cerebral aneu-rysm formation in rats. Int J Mol Med. 2009; 24: 353-9
|
|
|
|
|
|
27）Aoki T, Kataoka H, Ishibashi R, et al. Nifedipine inhibits the progression of an experimentally induced cerebral aneurysm in rats. Curr Neuro-vasc Res. 2008; 5: 37-45
|
|
|
|
|
|
28）Hasan DM, Mahaney KB, Brown RD, et al. Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke. 2011; 42: 3156-62
|
|
|
|
|